Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc., Cambridge, Massachusetts.
Department of Pharmacokinetics and Drug Metabolism, Amgen Research, Amgen Inc., Cambridge, Massachusetts
Drug Metab Dispos. 2020 Oct;48(10):861-872. doi: 10.1124/dmd.120.000064. Epub 2020 Aug 5.
Clearance (CL) prediction remains a significant challenge in drug discovery, especially when complex processes such as drug transporters are involved. The present work explores various in vitro to in vivo extrapolation (IVIVE) approaches to predict hepatic CL driven by uptake transporters in rat. Broadly, two different IVIVE methods using suspended rat hepatocytes were compared: initial uptake CL (PS) and intrinsic metabolic CL (CL) corrected by unbound hepatocytes to medium partition coefficient (Kp). Kp was determined by temperature method (Temp Kp), homogenization method (Hom Kp), and initial rate method (Kp). In addition, the impact of bovine serum albumin (BSA) on each of these methods was investigated. Twelve compounds, which are known substrates of organic anion-transporting polypeptides representing diverse chemical matter, were selected for these studies. As expected, CL alone significantly underestimated hepatic CL for all the test compounds. Overall, predicted hepatic CL using PS with BSA, Hom Kp with BSA, and Temp Kp showed the most robust correlation with in vivo rat hepatic CL. Adding BSA improved hepatic CL prediction for selected compounds when using the PS and Hom Kp methods, with minimal impact on the Temp Kp and Kp methods. None of the IVIVE approaches required an empirical scaling factor. These results suggest that supplementing rat hepatocyte suspension with BSA may be essential in drug discovery research for novel chemical matters to improve CL prediction. SIGNIFICANCE STATEMENT: The current investigation demonstrates that hepatocyte uptake assay supplemented with 4% bovine serum albumin is a valuable tool for estimating unbound hepatic uptake clearance (CL) and Kp. Based upon the extended clearance concept, direct extrapolation from these in vitro parameters significantly improved the overall hepatic CL prediction for organic anion-transporting polypeptide substrates in rat. This study provides a practical in vitro to in vivo extrapolation strategy for predicting transporter-mediated hepatic CL in early drug discovery.
清除率 (CL) 预测仍然是药物发现中的一个重大挑战,特别是当涉及到药物转运体等复杂过程时。本工作探讨了各种体外到体内外推 (IVIVE) 方法,以预测大鼠中由摄取转运体驱动的肝 CL。广义上,比较了两种使用悬浮大鼠肝细胞的不同 IVIVE 方法:初始摄取 CL(PS)和通过未结合肝细胞对介质分配系数(Kp)校正的内在代谢 CL(CL)。Kp 通过温度法(Temp Kp)、匀浆法(Hom Kp)和初始速率法(Kp)确定。此外,还研究了牛血清白蛋白 (BSA) 对这些方法中的每一种的影响。选择了 12 种化合物进行这些研究,这些化合物是代表不同化学物质的有机阴离子转运蛋白的已知底物。正如预期的那样,仅 CL 显著低估了所有测试化合物的肝 CL。总体而言,使用含 BSA 的 PS、含 BSA 的 Hom Kp 和 Temp Kp 预测的肝 CL 与体内大鼠肝 CL 相关性最强。当使用 PS 和 Hom Kp 方法时,添加 BSA 可改善选定化合物的肝 CL 预测,对 Temp Kp 和 Kp 方法的影响最小。不需要经验比例因子。这些结果表明,在新药研发中,用 BSA 补充大鼠肝细胞悬浮液可能对于提高 CL 预测非常重要。对于新型化学物质,补充牛血清白蛋白的肝细胞摄取测定是估计未结合肝摄取清除率 (CL) 和 Kp 的有价值的工具。基于扩展的清除率概念,从这些体外参数直接外推显著提高了大鼠有机阴离子转运蛋白底物的总体肝 CL 预测。本研究为预测早期药物发现中转运体介导的肝 CL 提供了一种实用的体外到体内外推策略。